Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Afinitor sales and marketing update

    The U.K.s NICE issued draft guidance recommending that Afinitor everolimus from Novartis be routinely available on the NHS to treat advanced renal cell carcinoma (RCC) that progressed during or after treatment with VEGF…

    Published on 1/16/2017
  • Pfizer sales and marketing update

    Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that the added benefit for Xalkori crizotinib from Pfizer was not proven vs. comparator therapy to treat c-ros …

    Published on 1/16/2017
  • Soliqua 100/33 sales and marketing update

    Sanofi launched Soliqua 100/33 insulin glargine/lixisenatide in the U.S. to treat Type II diabetes. Sanofi said the wholesale acquisition cost (WAC) for a 300 unit pen is $127, which the pharma says equals $19.90 a day …

    Published on 1/16/2017
  • Galafold sales and marketing update

    The U.K.s NICE issued a final evaluation determination recommending the use of Galafold migalastat from Amicus as first-line therapy for long-term treatment of Fabry disease in patients ages 16 and older who have an …

    Published on 1/9/2017
  • Kadcyla sales and marketing update

    The U.K.'s NICE issued draft guidance recommending against the use of Kadcyla trastuzumab emtansine from Roches Genentech unit to treat HER2-positive, locally advanced or metastatic breast cancer due to its high cost. …

    Published on 1/9/2017
  • Otezla sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Otezla apremilast from Celgene to treat psoriatic arthritis alone or in combination with DMARD therapy. The drug is recommended only if…

    Published on 1/9/2017
  • Clinical Genomics sales and marketing update

    Clinical Genomics launched its Colvera blood-based test in the U.S. to monitor the recurrence of colorectal cancer. Colvera is a PCR-based test that measures two epigenetically modified genes -- hyper-methylated …

    Published on 1/2/2017
  • HiberGene sales and marketing update

    HiberGene said its HG C. difficile test received CE Mark approval and that the company subsequently launched the diagnostic, which identifies Clostridium difficile from stool samples in under 60 minutes.HiberGene …

    Published on 1/2/2017
  • Proove TMD Profile sales and marketing news

    Proove launched its Proove TMD Profile test to assess and guide treatment of temporomandibular joint disorder. The test analyzes genetic variants in adrenergic and serotonergic pathways, and patient self-reported stress…

    Published on 1/2/2017
  • Adcetris sales and marketing update

    The U.K.s NICE issued draft guidance recommending against the use of Adcetris brentuximab vedotin from Takeda to treat CD30-positive Hodgkins lymphoma. Specifically, the agency recommends against Adcetris use for …

    Published on 12/19/2016
  • Cxbladder Monitor sales and marketing update

    Pacific Edge launched Cxbladder Monitor in the U.S. to identify bladder cancer patients at a low risk of recurrence. The urine-based gene expression test is indicated for use in patients actively being monitored for …

    Published on 12/19/2016
  • Harvoni sales and marketing update

    Express Scripts said it will expand the formulary of its Hepatitis Cure Value Program to include Gileads Harvoni ledipasvir/sofosbuvir. As part of an HCV pricing war, Harvoni had been kept out in favor of exclusive …

    Published on 12/19/2016
  • Lilly, Boehringer sales and marketing update

    Lilly and Boehringer launched Basaglar insulin glargine in the U.S. to treat Type I diabetes in adults and children and Type II in adults. The drug is a follow-on biologic to Lantus insulin glargine from Sanofi (…

    Published on 12/19/2016
  • Neratinib sales and marketing update

    Puma launched a managed access program outside the U.S. for neratinib to treat early stage HER2-positive breast cancer, HER2-positive metastatic breast cancer and HER2-mutated solid tumors. The oral inhibitor of HER1, …

    Published on 12/19/2016
  • Opdivo, Keytruda sales and marketing update

    In November, Japans Central Social Insurance Medical Council (Chuikyo) cut the price of cancer drug Opdivo nivolumab by 50%, effective February. Bristol-Myers has worldwide rights to Opdivo from Ono, except in Japan, …

    Published on 12/19/2016
  • Protalix sales and marketing update

    Protalix said the Brazilian Ministry of Health issued a letter requesting three shipments of alfataliglicerase to treat Type I Gaucher disease. The company estimated the revenues from the shipments to be about $24 …

    Published on 12/19/2016
  • GlaxoSmithKline sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending Nucala mepolizumab from GlaxoSmithKline as an add-on treatment for severe refractory eosinophilic asthma in adults. Earlier this year, NICE issued…

    Published on 12/12/2016
  • Keytruda sales and marketing update

    Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Mercks Keytruda pembrolizumab provides considerable added benefit vs. docetaxel in non-small cell lung cancer (NSCLC…

    Published on 12/12/2016
  • Lonsurf sales and marketing update

    Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that Servier's Lonsurf trifluridine/tipiracil provides "a hint of minor added benefit" vs. best supportive care to…

    Published on 12/12/2016
  • Qiagen sales and marketing update

    Qiagen launched its ipsogen CALR RGQ PCR Kit in Europe to aid in diagnosis of myeloproliferative neoplasms. The real-time PCR assay detects Type I and I calreticulin (CALR) mutations and mutations in the CALR exon 9 …

    Published on 12/12/2016
  • Sarepta sales and marketing update

    In a policy statement, UnitedHealth Group Inc. (NYSE:UNH, Minneapolis, Minn.) said it will cover Exondys 51 eteplirsen from Sarepta to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The policy …

    Published on 12/12/2016
  • BromSite sales and marketing update

    Sun launched BromSite bromfenac in the U.S. to treat postoperative inflammation and prevent pain during cataract surgery. BromSite consists of low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained …

    Published on 12/5/2016
  • CellMax Life sales and marketing update

    CellMax launched its CellMax-DNA Genetic Cancer Risk Test in the U.S. The saliva-based test uses the company's SMSEQ platform to detect mutations in 98 genes across 24 hereditary cancers.CellMax Life Inc., Sunnyvale, …

    Published on 12/5/2016
  • Cuvitru sales and marketing update

    Shire launched Cuvitru 20% subcutaneous immunoglobulin in the U.S. to treat primary immunodeficiency in patients =two years old. The wholesale acquisition cost (WAC) is $33.60 per mL.Shire plc (LSE:SHP; NASDAQ:SHPG), …

    Published on 12/5/2016
  • Imbruvica sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use Imbruvica ibrutinib from Johnson & Johnson to treat chronic lymphocytic leukemia (CLL) in previously treated patients or patients with…

    Published on 12/5/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993